Pharmaceutical giants Actavis and Forest Laboratories have reportedly agreed to forfeit the rights to four generic drugs in order to secure approval for their proposed merger.
Reports say the Federal Trade Commission found that under original terms of the merger, the market would likely face reduced competition when it came to …read more
Source: Global Competition Law Blogs